252 related articles for article (PubMed ID: 24141140)
1. Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.
Caretti A; Bragonzi A; Facchini M; De Fino I; Riva C; Gasco P; Musicanti C; Casas J; Fabriàs G; Ghidoni R; Signorelli P
Biochim Biophys Acta; 2014 Jan; 1840(1):586-94. PubMed ID: 24141140
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against A. fumigatus airways infection.
Caretti A; Torelli R; Perdoni F; Falleni M; Tosi D; Zulueta A; Casas J; Sanguinetti M; Ghidoni R; Borghi E; Signorelli P
Biochim Biophys Acta; 2016 Jun; 1860(6):1089-97. PubMed ID: 26922830
[TBL] [Abstract][Full Text] [Related]
3. Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.
Caretti A; Vasso M; Bonezzi FT; Gallina A; Trinchera M; Rossi A; Adami R; Casas J; Falleni M; Tosi D; Bragonzi A; Ghidoni R; Gelfi C; Signorelli P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):775-790. PubMed ID: 28439630
[TBL] [Abstract][Full Text] [Related]
4. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
[TBL] [Abstract][Full Text] [Related]
6. Myriocin modulates the altered lipid metabolism and storage in cystic fibrosis.
Signorelli P; Pivari F; Barcella M; Merelli I; Zulueta A; Dei Cas M; Rosso L; Ghidoni R; Caretti A; Paroni R; Mingione A
Cell Signal; 2021 May; 81():109928. PubMed ID: 33482299
[TBL] [Abstract][Full Text] [Related]
7. Modulators of sphingolipid metabolism reduce lung inflammation.
Dechecchi MC; Nicolis E; Mazzi P; Cioffi F; Bezzerri V; Lampronti I; Huang S; Wiszniewski L; Gambari R; Scupoli MT; Berton G; Cabrini G
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):825-33. PubMed ID: 21659660
[TBL] [Abstract][Full Text] [Related]
8. Cystic Fibrosis Defective Response to Infection Involves Autophagy and Lipid Metabolism.
Mingione A; Ottaviano E; Barcella M; Merelli I; Rosso L; Armeni T; Cirilli N; Ghidoni R; Borghi E; Signorelli P
Cells; 2020 Aug; 9(8):. PubMed ID: 32781626
[TBL] [Abstract][Full Text] [Related]
9. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.
Gardner AI; Haq IJ; Simpson AJ; Becker KA; Gallagher J; Saint-Criq V; Verdon B; Mavin E; Trigg A; Gray MA; Koulman A; McDonnell MJ; Fisher AJ; Kramer EL; Clancy JP; Ward C; Schuchman EH; Gulbins E; Brodlie M
Am J Respir Crit Care Med; 2020 Oct; 202(8):1133-1145. PubMed ID: 32569477
[No Abstract] [Full Text] [Related]
11. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.
John G; Yildirim AO; Rubin BK; Gruenert DC; Henke MO
Am J Respir Cell Mol Biol; 2010 Apr; 42(4):424-31. PubMed ID: 19502387
[TBL] [Abstract][Full Text] [Related]
12. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
[TBL] [Abstract][Full Text] [Related]
13. Reduction of ceramide de novo synthesis in solid tissues changes sphingolipid levels in rat plasma, erythrocytes and platelets.
Błachnio-Zabielska A; Baranowski M; Wójcik B; Górski J
Adv Med Sci; 2016 Mar; 61(1):72-7. PubMed ID: 26521206
[TBL] [Abstract][Full Text] [Related]
14. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
Stotland PK; Radzioch D; Stevenson MM
Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
[TBL] [Abstract][Full Text] [Related]
15. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction.
Hamada Y; Nagasaki H; Fujiya A; Seino Y; Shang QL; Suzuki T; Hashimoto H; Oiso Y
J Nutr Biochem; 2014 Dec; 25(12):1309-16. PubMed ID: 25283329
[TBL] [Abstract][Full Text] [Related]
16. Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells.
Bertelsen A; Elborn JS; Schock BC
J Cyst Fibros; 2021 Jul; 20(4):682-691. PubMed ID: 34112603
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA
Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of ceramide de novo biosynthesis rescue damages induced by cigarette smoke in airways epithelia.
Zulueta A; Caretti A; Campisi GM; Brizzolari A; Abad JL; Paroni R; Signorelli P; Ghidoni R
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jul; 390(7):753-759. PubMed ID: 28409208
[TBL] [Abstract][Full Text] [Related]
19. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL
Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
